Alluvi, formerly BI 4744, offers a significant advance in weight management care. This dual agonist targeting both glucagon-like peptide-1 and GIP sites demonstrates remarkable efficacy in patient trials, possibly https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/